| Serial number |
Requester |
product name
(Ingredient name) |
Clinical trial contents (summary) |
step |
Approval date |
| 1 |
Bukwang Pharmaceutical Co., Ltd. |
Levovir
Capsule 30mg
(Clevudine) |
Evaluation of the safety and effectiveness of commercially available drugs (hepatitis B drugs) for patients with moderate corona19 |
2 phase |
2020-04-14 |
| Safety and efficacy evaluation of commercially available drugs (hepatitis B drugs) for mild and moderate corona19 patients |
2 phase |
2021-01-07 |
| 2 |
Shinpoong Pharmaceutical Co., Ltd. |
Piramax tablet
(Pyrrolidine, altesunate) |
Safety, efficacy and safety comparative evaluation of commercially available drugs (antimalarial drugs) for mild or moderate Corona19 patients |
2 phase |
2020-05-13 |
| 3 |
Chong Kun Dang Co., Ltd. |
CKD-314
(Napamostat) |
Evaluation of the safety and effectiveness of commercially available drugs (anticoagulants) for hospitalized patients with COVID-19 pneumonia |
2 phase |
2020-06-17 |
| 4 |
crystal
Genomics Co., Ltd. |
CG-CAM20
(Duck start) |
Evaluation of the safety and effectiveness of commercially available drugs (pancreatitis drugs) for patients with COVID-19 |
2 phase |
2020-07-01 |
| 5 |
Daewoong Pharmaceutical Co., Ltd. |
DWJ1248 tablets
(Duck start) |
Evaluation of the safety and effectiveness of commercially available drugs (pancreatitis drugs) for mild and moderate corona19 patients |
2/3 phase |
2020-07-06 |
| Safety and efficacy evaluation of DWJ1248 and Remdesivir combination therapy for severe corona19 patients |
3-phase |
2020-12-31 |
| DWJ1248 safety and effectiveness evaluation for prevention after exposure to the Corona 19 virus, such as those in contact with corona 19 confirmed patients |
3-phase |
2021-01-22 |
| Evaluation of safety and pharmacokinetic characteristics according to dose after administration of DWJ1248 in healthy adults |
1 phase |
2021-02-23 |
| 6 |
Genexine |
GX-I7 |
Exploring the safety and preliminary effects of clinical trial drugs (anticancer drugs) for patients with COVID-19 |
1b phase |
2020-08-07 |
| 7 |
Celltrion |
CT-P59 |
Safety, tolerability, and virology evaluation for patients with mild corona19 |
1 phase |
2020-08-25 |
| Safety and efficacy evaluation in parallel with standard treatment for mild and moderate corona19 patients |
2/3 phase |
2020-09-17 |
| Preventive efficacy, virology, and safety evaluation for contact with COVID-19 patients |
3-phase |
2020-10-08 |
| 8 |
Lily Korea |
LY 3009104
(Varicitinib) |
Therapeutic confirmation test of commercially available drugs (arthritis drugs) for patients with COVID-19 |
3-phase |
2020-09-07 |
| 9 |
Daewoong Pharmaceutical Co., Ltd. |
DWRX2003
(Niclosamide) |
Evaluation of safety, tolerability, and pharmacokinetic characteristics of commercially available drugs (parasite repellents) for healthy adults |
1 phase |
2020-10-08 |
| 10 |
MSD Korea |
MK-4482 |
Evaluation of the safety, efficacy and pharmacokinetics of clinical trial drugs (influenza drugs) for hospitalized patients with COVID-19 |
2/3 phase |
2020-10-29 |
| 11 |
New Gen
Therapeutics |
New Genna Pharmost Tablet
(Napamostat) |
Evaluation of the safety, tolerability, and pharmacokinetic characteristics of commercially available drugs (anticoagulants) for healthy adult males |
1 phase |
2020-11-03 |
| 12 |
Dong Wha Pharm. |
DW2008S |
Comparative evaluation of the safety and effectiveness of clinical trial drugs (asthma drugs) for moderately corona 19 patients |
2 phase |
2020-11-23 |
| 13 |
Immunmed Co., Ltd. |
hzVSF-v13 |
The safety, efficacy, and safety of the standard therapy of clinical trial drug (influenza drug) for patients with moderate and severe corona19 (influenza drug) and the combined administration of hzVSF-v13 for each dose were compared with the standard therapy group alone. |
2 phase |
2020-12-07 |
| 14 |
Green Cross Wellness Co., Ltd. |
Rineneck
(Self-going singer
resolvent) |
Evaluation of the safety and effectiveness of commercially available drugs (liver function improvement drugs) for patients with moderate corona19 |
2a phase |
2021-02-26 |
– .
